webcast resource

Innovative imaging techniques to visualize drug targets

Considerations in assay development and its integration into drug development: Clinical trials and beyond into clinical practice

September 08, 2016 | Length: 24:14 min


Congress:Innovation and Biomarkers in Cancer Drug Development
Presenter:G. van Dongen

After finishing his PhD in molecular cell biology, he received a staff position at the Dept of Otolaryngology/Head and Neck Surgery VUmc at the laboratory for tumor biology, and in 2002 he became full professor. A main research line is on the use of targeted drugs like monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) for disease detection and therapy. In this field he introduced “immuno-PET” and “TKI-PET”, the PET imaging of radiolabeled mAbs and TKIs, respectively. In 2012 he became full professor at the Dept of Radiology & Nuclear Medicine. At the VUmc Cancer Center Amsterdam he is coordinating the program “disease profiling”. He is project leader for the foundation of a 160 M€ Imaging Center at VUmc. He is involved in the organization of a European physical infrastructure for translational research (EATRIS). Besides projects supported by cancer and technology foundations and EU, he has many collaborations with biotech, pharma and imaging companies. He has brought > 25 antibody conjugates, prepared in own licensed GMP facilities, in first-in-human studies. He supervised 15 PhD projects, is (co)author of > 170 peer-reviewed papers, and is inventor at several patents.

Category: Cancer;